Qualitative Study About Psychedelics Using in Psychiatric Disorders (PSYCHEQUALI)

July 21, 2026 updated by: University Hospital, Toulouse

Qualitative Study of the Self-administered Therapeutic Use of Psychedelics in People With Psychiatric Disorders

This study is set up to better understand the current use of psychedelics in France in the general population. The present focus on individuals who have used any type of psychedelic drug in order to suppress or alleviate a psychiatric symptom in the context of a diagnosed pathology. The data are collected during a semi-structured interview and then studied in a thematic analysis.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

20

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Toulouse, France, 31059
        • University Hospital toulouse

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adults patients self-administering psychodelic substances for therapeutic purposes

Description

Inclusion Criteria:

  • Patients diagnosed with a psychiatric disorder by a psychiatrist or general practitioner
  • Patients used psychedelic or related substances in order to treat psychiatric symptoms
  • Patients have given their oral non-opposition
  • Patients affiliated to a social security scheme

Exclusion Criteria:

  • Patients who don't speak or understand French
  • Patients under protection, guardianship or curators

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients using psychedelic substances
Adult patients self-administering psychedelic substances in psychiatric disorders
Diagnostic test: Interview
An interview will be conducted to describe the experiences of people with psychiatric disorders who use psychedelic substances for therapeutic purposes

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Experiences of people using psychedelic substances
Time Frame: Baseline
Experiences description of people with psychiatric disorders who use psychedelic substances for therapeutic purposes will be assessed by interview
Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Profile of people using psychedelic substances
Time Frame: Baseline
The profile of people with psychiatric disorders who use psychedelic substances for therapeutic purposes will be assessed by interview
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Toulouse

Investigators

  • Principal Investigator: Antoine YRONDI, MD, University Hospital, Toulouse

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 30, 2023

Primary Completion (Actual)

November 15, 2024

Study Completion (Actual)

November 15, 2024

Study Registration Dates

First Submitted

August 22, 2023

First Submitted That Met QC Criteria

August 22, 2023

First Posted (Actual)

August 28, 2023

Study Record Updates

Last Update Posted (Actual)

July 23, 2026

Last Update Submitted That Met QC Criteria

July 21, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RC31/23/0396
  • 2023-A01575-40 (Other Identifier: ID-RCB)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe